![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
P1084s: Impact of maternal tenofovir disoproxil fumarate
(TDF) use on HIV-exposed newborn bone mineral content
|
|
|
Reported by Jules Levin
CROI 2016 Feb 22-26 Boston
from Jules: In another study, report to be emailed out right after this: Roux (abs 808) conducted a study whose objective was: "we investigated the association between duration of in utero TDF exposure and linear growth in the first year of life of HIV-exposed uninfected (HEU) children [- and reported -] Overall, these data demonstrate a reassuring lack of association between duration of TDF exposure in utero and linear growth in the first year of life in breastfed infants - Linear growth appears clinically unaffected by in utero exposure to tenofovir, but longer follow-up of HEU children exposed to ART in utero is warranted".
Siberry GK, Tierney C, Stranix-Chibanda L, Marr C, Shepherd JA, Browning R, Kalkwarf H, George K and Fowler MG for the IMPAACT P1084s Study Team
WEBCAST:http://www.croiwebcasts.org/console/player/29477?mediaType=audio&
![CROI1](../images/031416/031416-4/CROI1.gif)
![CROI2](../images/031416/031416-4/CROI2.gif)
![CROI3](../images/031416/031416-4/CROI3.gif)
![CROI4](../images/031416/031416-4/CROI4.gif)
![CROI5](../images/031416/031416-4/CROI5.gif)
![CROI6](../images/031416/031416-4/CROI6.gif)
![CROI7](../images/031416/031416-4/CROI7.gif)
![CROI8](../images/031416/031416-4/CROI8.gif)
![CROI9](../images/031416/031416-4/CROI9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|